Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0024)
| Name |
Tert-Butylhydroquinone
|
||||
|---|---|---|---|---|---|
| Synonyms |
tert-Butylhydroquinone; 1948-33-0; TBHQ; 2-tert-Butylhydroquinone; 2-tert-butylbenzene-1,4-diol; T-BUTYLHYDROQUINONE; MTBHQ; t-Butyl hydroquinone; 2-t-Butylhydroquinone; Mono-tert-butylhydroquinone; Sustane; 2-tert-Butyl-1,4-benzenediol; Mono-tertiarybutylhydroquinone; tert-Butyl-1,4-benzenediol; Tenox TBHQ; tertiary-Butylhydroquinone; Banox 20BA; Hydroquinone, tert-butyl-; 2-(1,1-Dimethylethyl)-1,4-benzenediol; 1,4-Benzenediol, 2-(1,1-dimethylethyl)-; 2-tert-Butyl(1,4)hydroquinone; 2-tertiary-butylhydroquinone; Tertiary butylhydroquinone; tert-Butylhydrochinone; t-BHQ; 2-(tert-butyl)benzene-1,4-diol; 2-t-Butyl-1,4-benzenediol; Hydroquinone, t-butyl-; Butylhydroquinone, tert-; NSC 4972; Tenox 20; monotertiary butyl hydroquinone; CCRIS 1447; HSDB 838; CHEBI:78886; 1,4-Benzenediol (1,1-dimethylethyl)-; NSC4972; Eastman MTBHQ; NSC-4972; EINECS 217-752-2; MFCD00002344; BRN 0637923; DTXSID6020220; AI3-61039; tert-butyl-hydroquinone; UNII-C12674942B; 2-(1,1-dimethylethyl)benzene-1,4-diol; DTXCID60220; BUTYLHYDROQUINONE,TERT-; INS NO.319; C12674942B; INS-319; EC 217-752-2; HYDROQUINONE,TERTIARY BUTYL; 2-tert-butyl-1,4-dihydroxybenzene; NCGC00013051-05; E319; E-319; TERT-BUTYLHYDROQUINONE (II); TERT-BUTYLHYDROQUINONE [II]; 2-(tert-Butyl)benzene-1,4-diol(may occur to produce black solid); EYK; TERTIARY BUTYLHYDROQUINONE (MART.); TERTIARY BUTYLHYDROQUINONE [MART.]; CAS-1948-33-0; Butylhydroquinone, t-; tert-butyl hydroquinone; 2-(tert-Butyl)-p-hydroquinone; Sustane TBHQ; Tenox TBHO; Tenox TBHQTBHQ; t-butyl-hydroquinone; THBQ; 2-t-butyl hydroquinone; tert.-butyl hydroquinone; 2-tert-butyl-hydroquinone; TBHQ [INCI]; TBHQ [FCC]; NCIStruc1_000241; NCIStruc2_000017; SCHEMBL26745; tert-Butylhydroquinone, 97%; MLS002222348; CHEMBL242080; NCI4972; WLN: QR DQ BX1&1&1; KUC109743N; T-BUTYLHYDROQUINONE [HSDB]; 1,4-dihydroxy-2-tert-butylbenzene; Tox21_110006; Tox21_110007; Tox21_202309; Tox21_300081; BDBM50065387; CCG-37948; NCGC00013051; s4990; STK372011; AKOS003627061; CS-5774; DB07726; 2-TERT-BUTYL-1,4-HYDROQUINONE; NCGC00013051-01; NCGC00013051-02; NCGC00013051-03; NCGC00013051-04; NCGC00013051-06; NCGC00013051-07; NCGC00013051-08; NCGC00013051-09; NCGC00013051-10; NCGC00090788-01; NCGC00090788-02; NCGC00090788-03; NCGC00090788-04; NCGC00254178-01; NCGC00259858-01; AC-10579; BS-15862; NCI60_004196; SMR001253806; SY001798; 2-(1,1-DIMETHYLETHYL)HYDROQUINONE; HYDROQUINONE,TERTIARY BUTYL [VANDF]; KSC-241-078-1; tert-Butylhydroquinone, analytical standard; HY-100489; B0833; FT-0652102; 2-(1,1-Dimethylethyl)-1,4-benzenediol, 9CI; D70420; EN300-120878; Q662443; W-107698; BRD-K36452089-001-01-8; BRD-K36452089-001-02-6; F0001-0696; Z1255402624
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C10H14O2
|
||||
| IUPAC Name |
2-tert-butylbenzene-1,4-diol
|
||||
| Canonical SMILES |
CC(C)(C)C1=C(C=CC(=C1)O)O
|
||||
| InChI |
InChI=1S/C10H14O2/c1-10(2,3)8-6-7(11)4-5-9(8)12/h4-6,11-12H,1-3H3
|
||||
| InChIKey |
BGNXCDMCOKJUMV-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Marker/Suppressor | ||||
| Responsed Disease | Ulcerative colitis | ICD-11: DD71 | |||
| Pathway Response | Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | HIEC-6 cells | Normal | Homo sapiens | CVCL_6C21 | |
| In Vivo Model |
Male C57/BL6 mice (eight weeks old, 18-20 g) were purchased from Chengdu Dossy Experimental Animals (China). All the mice were housed in plastic cages with free access to food and water at 25 with a 12 h light/dark cycle. The mice were randomly divided into four groups (n = 6 mice/group): the control group, 5-FU group, 5-FU + TBHQ group, and 5-FU + Fer-1 group. 50 mg/kg body weight 5-FU was intraperitoneally (i.p.) injected into the mice of the 5-FU, 5-FU + TBHQ and 5-FU + Fer-1 group per day for five days to induce intestinal mucositis. Starting on the same day, the mice in the 5-FU + TBHQ and 5-FU + Fer-1 group were treated with TBHQ (10 mg/kg body weight; in DMSO, i.p. injection) or Fer-1 (2.5 mol/kg body weight; in DMSO; i.p. injection) once daily for eight days (days 18). Starting on the same day, the mice of the 5-FU group were treated with equivalent volumes of dimethyl sulfoxide (DMSO) for eight days.
Click to Show/Hide
|
||||
| Response regulation | Ferroptosis was shown to be involved in 5-FU-induced intestinal mucositis, and Tertiary butylhydroquinone markedly hampered its activation. Mechanistically, TBHQ activated Nrf2 effectively and selective Nrf2 knockdown significantly reduced the anti-ferroptotic functions of TBHQ in 5-FU-treated HIECs. | ||||